BOC Sciences provides structure based drug design service for research teams that need to turn three-dimensional target information into actionable hit discovery and lead optimization decisions. As part of our structure-based drug discovery capability, our integrated computer-aided drug discovery platform combines protein structure assessment, pocket analysis, molecular docking, virtual screening, binding mode interpretation, molecular dynamics, free energy estimation, and medicinal chemistry feedback. We support pharmaceutical, biotechnology, chemical biology, and specialty molecule research teams that need reliable compound prioritization before synthesis, screening, or analog expansion.
Structure-based drug design (SBDD) is a rational drug discovery and optimization strategy that uses the three-dimensional structure of a target protein or biological macromolecule to guide molecular design. By analyzing high-resolution structural information such as active pockets, allosteric sites, and protein-protein interaction interfaces, SBDD applies the "lock-and-key" principle to identify how candidate molecules may fit, bind, and interact with key residues. Combined with molecular docking and virtual screening, this approach helps researchers design or prioritize molecules with stronger binding affinity, improved selectivity, and clearer optimization directions. SBDD is widely used in kinase inhibitor design, covalent drug design, PROTAC optimization, and molecular glue discovery.
Our team supports receptor-based drug design by using high-resolution three-dimensional target information from X-ray crystallography, cryo-EM, NMR, homology modeling, or predicted protein structures. We evaluate active pocket geometry, allosteric sites, protein-protein interaction interfaces, residue-level interaction patterns, and binding energy distribution to define a reliable design hypothesis. Through molecular docking, structure-based virtual screening, and free energy perturbation analysis, the BOC Sciences team assesses atomic-level complementarity between target pockets and compound libraries, helping clients rapidly enrich high-affinity hit candidates. This service is particularly suitable for structurally characterized kinases, proteases, and nuclear receptor targets, where binding modes can explain selectivity and guide each round of SAR optimization.
When a reliable target structure is unavailable or difficult to obtain, our scientists provide ligand-based drug design service using known active ligands as the starting point. Pharmacophore modeling, molecular similarity searching, QSAR prediction, and activity model construction are applied to identify new scaffolds with related functional features. This strategy helps overcome the limitation of structure-limited targets and is especially valuable for GPCRs, dynamically flexible targets, and complex proteins that have not been successfully crystallized. By incorporating AI-assisted molecular graph analysis and ADMET prediction, we help clients improve activity prediction, property balance, and compound prioritization even when structural information is incomplete.
For fragment-based drug design projects, we start from low-molecular-weight fragment libraries and identify weak but meaningful binding events that can serve as efficient starting points. Sensitive fragment detection and structural interpretation strategies, including ligand-observed NMR, X-ray fragment screening, and surface plasmon resonance, are used to locate key hot spots on the target. Fragment-target structural information then guides fragment growing, linking, or merging, gradually converting small high-ligand-efficiency fragments into higher-affinity lead molecules. This service is well suited for challenging targets such as kinase allosteric pockets and protein-protein interaction interfaces, where traditional high-throughput screening may miss novel chemical starting points and alternative mechanisms of action.
In de novo drug design projects, the BOC Sciences team generates novel molecular scaffolds directly from the chemical and spatial constraints of a target binding pocket. Generative AI models, structure-guided scoring, molecular dynamics information, and multi-parameter optimization are combined to design molecules that match pocket geometry, electrostatics, hydrophobic regions, and conformational requirements. Because this strategy does not depend on existing active compounds, it helps clients explore differentiated chemical space in target areas where conventional inhibitor scaffolds are already crowded. We simultaneously consider predicted binding affinity, synthetic accessibility, physicochemical properties, and ADMET-related features, making this service valuable for allosteric modulator design, molecular glue discovery, and innovative mechanism-oriented compound generation.
BOC Sciences helps discovery teams move from target structure to pocket definition, docking strategy, virtual screening, pose validation, analog design, and experiment-ready compound prioritization.
BOC Sciences provides modular and end-to-end SBDD support for clients working on enzymes, receptors, ion channels, transporters, protein-protein interaction targets, nucleic acid-binding proteins, and emerging targets with limited ligand precedents. Our deliverables are designed to help clients decide what to synthesize, what to screen, and how to optimize a molecular series.
| Service Module | Representative Capabilities & Project Outputs |
| Target Structure Preparation | Receptor model review, chain selection, binding site definition, cofactor handling, water network assessment, protonation state assignment, pocket quality scoring, and docking-ready structure generation |
| Binding Site & Druggability Analysis | Orthosteric and allosteric pocket mapping, hot-spot identification, buried surface assessment, hydrophobic and polar region analysis, induced-fit risk review, and ligandability ranking |
| Molecular Docking | Pose prediction, interaction fingerprint analysis, constraint docking, covalent docking concept assessment, induced-fit docking, ensemble docking, rescoring, and medicinal chemistry review of predicted binding modes |
| Structure-Based Virtual Screening | Large-scale docking campaigns, fragment screening, scaffold-focused screening, library design, hit clustering, property filtering, and prioritized compound list generation |
| Fragment & Scaffold Design | Fragment-based drug discovery support, fragment growing, fragment linking, scaffold hopping, hinge binder replacement, bioisostere exploration, and pocket-complementary substituent design |
| De Novo Ligand Design | Structure-guided molecule generation, pharmacophore constraint design, 3D shape matching, synthetic accessibility review, analog enumeration, and ranked design proposal preparation |
| Molecular Dynamics & Free Energy Estimation | Complex stability evaluation, ligand RMSD and RMSF review, contact persistence, water bridge analysis, MM/GBSA or MM/PBSA ranking, and conformational comparison of analogs |
| SAR & Selectivity Hypothesis Building | Structure-activity relationship analysis, off-target pocket comparison, analog vector recommendation, selectivity pocket exploitation, and risk-based prioritization |
| Experimental Follow-Up Planning | Compound shortlist preparation, high-throughput screening set selection, orthogonal assay recommendation, reference compound selection, and data interpretation support |
Share your target structure, ligand series, known activity data, screening goal, protein flexibility concern, preferred compound source, and downstream synthesis needs. Our specialists will design a project-specific plan covering receptor preparation, docking protocol, screening library, simulation depth, analog design, and experimental follow-up strategy.
Understand the client's target background and project stage, and define the service scope, including structure determination, virtual screening, de novo design, and optimization, as well as success criteria, intellectual property ownership, and confidentiality agreement.
Evaluate the quality of existing PDB structures, including resolution, completeness, and ligand state. If no usable structure is available, plan experimental structure determination by XRD/Cryo-EM/NMR. Analyze active pocket volume, depth, and hydrophobic/polar distribution; identify orthosteric, allosteric, and transient pockets; and evaluate target druggability risks.
Integrate compound libraries, select computational methods according to target characteristics, execute docking/screening calculations, molecular dynamics validation, free energy fine ranking, and related analyses.
Cluster and prioritize hits, translate 3D binding modes into structure-activity relationship hypotheses, and propose specific optimization directions, including R-group replacement, linker adjustment, and scaffold hopping. Provide all raw files, including structure files, docking poses, MD trajectories, compound lists (SDF/Excel), scripts, and parameters.
Many SBDD projects fail because the receptor model is used too early without assessing missing residues, mobile loops, incorrect protonation, water molecules, cofactors, or allosteric alternatives. BOC Sciences reviews structural data before screening, prepares multiple receptor states when needed, and compares pocket geometry against known ligand features. This helps clients avoid ranking compounds against an unrealistic binding site.
A high docking score alone does not guarantee a useful hit. False positives may arise from strained ligand conformations, buried polar groups, unstable water displacement, reactive substructures, or unrealistic poses. BOC Sciences applies interaction fingerprints, pose inspection, property filters, consensus scoring, and medicinal chemistry review to identify molecules that are both structurally plausible and experimentally actionable.
When analog changes produce weak or inconsistent activity shifts, structure-guided interpretation can reveal whether the series is missing a key hydrogen bond, occupying the wrong subpocket, or overextending into solvent. BOC Sciences integrates docking, molecular dynamics, hit to lead analysis, and matched-pair reasoning to propose analog vectors with stronger mechanistic support.
A computationally attractive analog may still be impractical if the proposed vector requires a difficult route, unstable intermediate, or poorly controlled substitution pattern. BOC Sciences connects SBDD results with custom synthesis, intermediates synthesis, and reference compound synthesis support, allowing design ideas to be evaluated against real chemical feasibility.
Collaborate with BOC Sciences to access receptor preparation, docking campaigns, virtual screening, molecular dynamics, free energy ranking, analog design, and integrated follow-up support for discovery programs that require structure-guided decisions.
BOC Sciences brings together computational chemists, medicinal chemists, synthetic chemists, and assay-aware project scientists to support structure-guided discovery from target model review to compound prioritization. Our team designs SBDD workflows that connect predicted binding modes with practical medicinal chemistry decisions.
We support early pocket exploration, focused hit finding, fragment expansion, scaffold hopping, analog series optimization, and rescue projects for stalled SAR. Clients can start with a single target model or combine SBDD with lead discovery, screening, synthesis, and follow-up testing services.
Our reports focus on decision-making value: ranked compounds, annotated poses, contact maps, critical residue analysis, analog vectors, property risks, and synthesis-aware recommendations. This makes the output easier to use in project meetings, compound ordering discussions, and next-round design planning.
BOC Sciences can connect computational prioritization with pharmacological activity test services, cell-based assay services, and DMPK services when clients need orthogonal data to confirm or refine a structure-guided hypothesis.
Client Needs: A medicinal chemistry team had a weak kinase hinge-binding series with good ligand efficiency but poor selectivity across related kinase models. They needed structure-guided analog ideas before committing resources to the next synthesis cycle.
Challenges: The hinge interaction was conserved, and the available crystal structure showed a solvent-exposed vector that could improve selectivity but also increased polarity. Standard docking ranked many analogs similarly, making prioritization difficult.
Solution: We prepared three kinase conformations, docked 186 enumerated analogs, and clustered 42 high-ranking poses by hinge contact, solvent vector, and back-pocket occupancy. Molecular dynamics was applied to eight representative complexes, while MM/GBSA ranking and interaction fingerprint analysis identified two substituent patterns that maintained hinge binding and exploited a non-conserved hydrophobic subpocket.
Outcome: The client received a focused analog list with annotated binding modes and substituent priorities for the next design cycle.
Client Needs: A discovery group identified a fragment bound near a catalytic serine in an enzyme pocket and wanted to grow the fragment toward a secondary polar region without disrupting the original anchor interaction.
Challenges: The fragment had only one reliable exit vector, and the pocket contained a structured water network that could either stabilize or destabilize new analogs. The team needed a design strategy that balanced potency potential with synthetic feasibility.
Solution: We used the fragment pose as a fixed anchor, generated 72 growth ideas, and filtered them by vector geometry, polar contact quality, synthetic accessibility, and ligand efficiency. Twenty designs were redocked with water-aware constraints, and six complexes were refined through short molecular dynamics runs to verify anchor persistence and identify substituents likely to displace unfavorable waters.
Outcome: The final report provided six prioritized fragment-growth designs, pocket interaction maps, and a synthesis-aware ranking table.
Client Needs: A chemical biology team wanted small-molecule modulators for an allosteric pocket discovered from a predicted protein structure and mutational literature. No high-confidence co-crystal ligand was available.
Challenges: The pocket was shallow and partly formed by a mobile loop. Early docking against a single protein model produced unstable poses and repeatedly selected flat aromatic structures with limited development value.
Solution: We built an ensemble of five receptor states from loop-refined structures and screened 48,000 compounds using pharmacophore constraints derived from conserved pocket residues. After clustering 320 top-ranked compounds, we applied interaction fingerprint filters, property review, and 120 ns molecular dynamics on 12 complexes. The workflow prioritized scaffold diversity while excluding poses dependent on unrealistic loop closure.
Outcome: The client received a balanced shortlist of chemically diverse candidates and a refined allosteric binding hypothesis for experimental testing.
Structure-based drug design is especially useful when a reliable 3D structure of the target protein is available from X-ray crystallography, cryo-EM, NMR, or a carefully evaluated computational model. It helps research teams understand binding pockets, prioritize hit compounds, explain structure-activity relationships, and guide lead optimization. BOC Sciences can assess the target structure, identify druggable sites, compare known ligands, and combine molecular docking, virtual screening, pharmacophore constraints, molecular dynamics, and binding free energy analysis to help clients select more promising compounds for synthesis or testing.
Useful starting materials include the target protein structure, target name, known active ligands, inactive or weak reference molecules, key residues, candidate compound libraries, preferred binding regions, existing SAR data, and planned downstream assays. When a complete experimental structure is not available, BOC Sciences can support homology modeling, AlphaFold model evaluation, pocket identification, and structure preparation. We carefully review missing residues, protonation states, cofactors, metal ions, crystallographic waters, and binding-site geometry because these factors can strongly affect docking poses, scoring reliability, and optimization decisions.
Molecular docking is valuable for predicting possible ligand binding modes, identifying key interactions, and ranking compounds at an early stage, but docking scores should not be treated as direct activity values. Scoring can be influenced by protein flexibility, water-mediated interactions, protonation states, conformational sampling, and limitations of the scoring function. BOC Sciences typically strengthens interpretation by using consensus scoring, interaction filtering, pose inspection, rescoring, molecular dynamics stability checks, and MM/GBSA or related free energy calculations, helping clients make more reliable decisions before synthesis or experimental validation.
In lead optimization, SBDD helps explain why specific substituents improve or weaken binding rather than simply ranking compounds. BOC Sciences analyzes hydrogen bonding, hydrophobic packing, π-π stacking, salt bridges, conformational strain, solvent-exposed regions, and unoccupied pocket space to propose practical structural modifications. For compound series, we can integrate molecular docking, 3D-QSAR, molecular dynamics, binding free energy decomposition, and ADMET-related computational assessment to help clients balance binding affinity, selectivity, physicochemical properties, and developability during iterative medicinal chemistry design.
Typical project outputs include target structure assessment, binding pocket analysis, ligand preparation details, docking parameters, virtual screening rankings, prioritized compound lists, protein-ligand interaction maps, key residue interpretation, molecular dynamics trajectory analysis, RMSD/RMSF profiles, hydrogen bond occupancy, estimated binding free energy, and actionable structure optimization suggestions. For drug discovery, materials-related bioactive molecule design, or personal care ingredient development, BOC Sciences can also provide compound modification ideas, prioritized synthesis recommendations, and next-round screening strategies so computational results can be translated into practical experimental plans.
BOC Sciences gave us access to both physical and virtual compound libraries, which made our structure-based screening project much more efficient. The diversity of scaffolds and target-focused compound selection helped us identify several promising starting points for follow-up evaluation.
— Dr. Carroll, Medicinal Chemistry Director
The screening workflow was well organized and scientifically clear. Their team handled docking, compound prioritization, binding mode analysis, and result interpretation with strong technical expertise, allowing us to focus on the most relevant candidates instead of reviewing large numbers of low-confidence hits.
— Burton, Discovery Project Lead
After the computational design stage, we needed several analogs that were not commercially available. BOC Sciences supported the follow-up custom synthesis work and helped convert structure-guided design ideas into compounds that could be evaluated in our next research cycle.
— Dr. Keller, Principal Scientist
The project moved forward quickly from target structure review to compound ranking and report delivery. We appreciated the clear communication, practical recommendations, and timely output, which helped our team make faster decisions for the next round of compound selection.
— Morrison, Senior Research Manager
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
